Abstract
Clopidogrel is a thienopyridine that selectively and irreversibly inhibits the ADP purinergic receptor P2Y12 and the subsequent ADP-mediated platelet activation. Clopidogrel has been approved for clinical use as clopidogrel hydrogen sulfate (bisulfate) salt. The clinical usefulness of clopidogrel bisulfate salt has been proved in a wide variety of large scale clinical trials, thus clopidogrel bisulfate has been extensively used in a large spectrum of patients been under thrombotic risk. Recently, several generic clopidogrel formulations have been approved for clinical use. Consequently, clopidogrel is currently a cost-effective antiplatelet agent. Only small studies have compared the pharmacokinetic and pharmacodynamic properties of various clopidogrel generic salt formulations with the innovator bisulfate salt. In addition few data are available concerning the clinical efficacy and safety of these generic clopidogrel formulations in order to guide clinicians in deciding when generic substitution is appropriate. The aim of this review is to summarize the physicochemical properties as well as the pharmacokinetic and pharmacodynamic characteristics of the generic clopidogrel salts. We also critically present existing data on the clinical efficacy and safety of the generic clopidogrel formulations compared with the innovator clopidogrel bisulfate salt in patients with cardiovascular disease.
Keywords: Bioequivalence, cardiovascular disease, clopidogrel, generic clopidogrel, pharmacokinetics, pharmacodynamics, platelets.
Current Vascular Pharmacology
Title:Clopidogrel Generic Formulations in the Era of New Antiplatelets: A Systematic Review
Volume: 12 Issue: 5
Author(s): Maria E. Tsoumani, Kallirroi I. Kalantzi, Ioannis A. Goudevenos and Alexandros D. Tselepis
Affiliation:
Keywords: Bioequivalence, cardiovascular disease, clopidogrel, generic clopidogrel, pharmacokinetics, pharmacodynamics, platelets.
Abstract: Clopidogrel is a thienopyridine that selectively and irreversibly inhibits the ADP purinergic receptor P2Y12 and the subsequent ADP-mediated platelet activation. Clopidogrel has been approved for clinical use as clopidogrel hydrogen sulfate (bisulfate) salt. The clinical usefulness of clopidogrel bisulfate salt has been proved in a wide variety of large scale clinical trials, thus clopidogrel bisulfate has been extensively used in a large spectrum of patients been under thrombotic risk. Recently, several generic clopidogrel formulations have been approved for clinical use. Consequently, clopidogrel is currently a cost-effective antiplatelet agent. Only small studies have compared the pharmacokinetic and pharmacodynamic properties of various clopidogrel generic salt formulations with the innovator bisulfate salt. In addition few data are available concerning the clinical efficacy and safety of these generic clopidogrel formulations in order to guide clinicians in deciding when generic substitution is appropriate. The aim of this review is to summarize the physicochemical properties as well as the pharmacokinetic and pharmacodynamic characteristics of the generic clopidogrel salts. We also critically present existing data on the clinical efficacy and safety of the generic clopidogrel formulations compared with the innovator clopidogrel bisulfate salt in patients with cardiovascular disease.
Export Options
About this article
Cite this article as:
Tsoumani E. Maria, Kalantzi I. Kallirroi, Goudevenos A. Ioannis and Tselepis D. Alexandros, Clopidogrel Generic Formulations in the Era of New Antiplatelets: A Systematic Review, Current Vascular Pharmacology 2014; 12 (5) . https://dx.doi.org/10.2174/15701611113119990135
DOI https://dx.doi.org/10.2174/15701611113119990135 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Pulmonary Hypertension in Idiopathic Pulmonary Fibrosis
Clinical Anti-Inflammatory & Anti-Allergy Drugs (Discontinued) Bone Loss and Osteoporosis are Associated with Conversion from Mild Cognitive Impairment to Alzheimer’s Disease
Current Alzheimer Research Inflammation as a Therapeutic Target for Various Deadly Disorders: A Review
Current Drug Targets The Use of Statins in Respiratory Diseases
Current Respiratory Medicine Reviews Drug-Induced QTc Interval Prolongation: A Multicenter Study to Detect Drugs and Clinical Factors Involved in Every Day Practice
Current Drug Safety Modified Polysaccharides as Versatile Materials in Controlled Delivery of Antidegenerative Agents
Current Pharmaceutical Design Nutrition, Brain Aging, and Alzheimers Disease
Current Nutrition & Food Science HIV-1, Methamphetamine and Astrocyte Glutamate Regulation: Combined Excitotoxic Implications for Neuro-AIDS
Current HIV Research Cardiovascular Effects of Losartan and Its Relevant Clinical Application
Current Medicinal Chemistry Anti-Atherosclerotic Therapy Based on Botanicals
Recent Patents on Cardiovascular Drug Discovery Smoking and Hypertension: Effects on Clinical, Biochemical and Pathological Variables Due to Isolated or Combined Action on Cardiovascular System
Current Pharmaceutical Design Possible Underestimation by Sports Medicine of the Effects of Early Physical Exercise Practice on the Prevention of Diseases in Adulthood
Current Diabetes Reviews Aortic Stenosis, Aortic Regurgitation and Arterial Hypertension
Current Vascular Pharmacology Development of a Registry for Down Syndrome in the Gulf Area of the Middle East
Applied Clinical Research, Clinical Trials and Regulatory Affairs Type 2 Diabetes: An Atherothrombotic Syndrome
Current Molecular Medicine Anti-Atherosclerotic Molecules Targeting Oxidative Stress and Inflammation
Current Pharmaceutical Design Phytochemicals: Potential in Management of Climacteric Neurobiology
Current Pharmaceutical Design Editorial (Thematic Issue: Induced Pluripotent Stem Cells (iPSCs) in the Gastroenterology and Hepatology: from Basic Research to Clinical Applications)
Current Stem Cell Research & Therapy Environmental Factors and Hypertension
Current Pharmaceutical Design The Secondary Heart Field: Understanding Conotruncal Defects from a Developmental Perspective
Current Cardiology Reviews